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Background: Diguanylate cyclases (DGCs) regulate biofilm formation and motility in bacteria by synthesizing the
second messenger cyclic di-GMP (c-di-GMP) in response to environmental stimuli. DGC enzymatic activity is believed to
be dependent on the presence of a GG(D/E)EF active site motif, however approximately 25% of known DGCs contain a
degenerate active site. The Vibrio cholerae protein VCA0965 contains an AGDEF active site and is presumed to be an
inactive DGC.
Results: Ectopic expression of VCA0965 in V. cholerae causes a 3-fold reduction in flagellar-based motility. Additionally,
an RXXD allosteric inhibition mutant of VCA0965 strongly inhibited motility and stimulated biofilm formation. This
activity was lost when the active site of VCA0965 was mutated to AGDAF, suggesting that VCA0965 synthesizes
c-di-GMP. In support of this, ectopic expression of VCA0965 and VCA0965 containing a mutation in its RXXD motif
significantly increased the intracellular c-di-GMP levels in V. cholerae and Escherichia coli. Furthermore, we found
that purified VCA0965 was able to synthesize c-di-GMP in vitro. Systematic mutation of the first amino acid in the
AGDEF motif of VCA0965 revealed that glycine, methionine, and histidine also produced an active DGC capable of
inhibiting motility and increasing the intracellular concentration of c-di-GMP in V. cholerae.
Conclusions: Based on these results, we conclude that VCA0965 is capable of c-di-GMP synthesis and that the first
amino acid of the GG(D/E)EF motif is more tolerant of substitutions than currently appreciated.
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Cyclic di-GMP (c-di-GMP) is a bacterial second mes-
senger that is widely utilized by bacteria, with more
than 80% of sequenced bacteria predicted to use this
signal [1,2]. C-di-GMP controls a variety of phenotypes,
including biofilm formation, motility, and virulence in
multiple bacteria [3-8]. In Vibrio cholerae, high levels of
c-di-GMP induce biofilm formation, reduce swimming
motility, and inhibit colonization in a murine infection
model [9,10]. These c-di-GMP associated behaviors are
enacted through c-di-GMP binding to a variety of re-
ceptor proteins [5,11-13] and, potentially to one of two* Correspondence: watersc3@msu.edu
1Department of Microbiology and Molecular Genetics, Michigan State
University, East Lansing, MI 48824, USA
2BEACON Center for the Study of Evolution in Action, Michigan State
University, 5180 BPS 567 Wilson Road, East Lansing, MI 48824, USA
© 2014 Hunter et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orclasses of riboswitches [14,15]. Intracellular levels of c-
di-GMP are controlled through synthesis from two mol-
ecules of GTP by diguanylate cyclases (DGC) [16] and
degradation to pGpG or GMP by phosphodiesterases
(PDE) [6,17].
DGCs are characterized by the presence of a con-
served GGDEF domain composed of approximately 200
amino acids [18]. These domains are believed to require
the specific amino acid sequence GG(D/E)EF in their ac-
tive site (referred to as A-site here) in order to retain
their enzymatic activity. In addition to their active site
motif, approximately 53% of GGDEFs contain an RXXD
motif [1]. The RXXD motif is a feedback inhibition site
(referred to as the I-site here) located near the active
site, which specifically binds to dimeric c-di-GMP to
non-competitively inhibit enzyme activity [19]. EAL do-
mains are one of the two enzymatic domains that con-
tain c-di-GMP specific phosphodiesterase (PDE) activity,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hunter et al. BMC Microbiology 2014, 14:22 Page 2 of 10
http://www.biomedcentral.com/1471-2180/14/22the other being the HD-GYP domain [6,17]. Approxi-
mately 67% of DGCs are multi-domain proteins, con-
taining at least one partner domain, with the most
common partner domain being the EAL domain [1].
Interestingly, in more than 40% of these EAL-GGDEF
proteins (and in 24% of DGCs in general) the GGDEF
active site is degenerate at one or more amino acids,
suggesting that many of these proteins are incapable of
c-di-GMP synthesis [1].
One explanation for the high frequency of degenerate
DGCs is that these proteins in some cases act as c-di-
GMP receptors by binding to c-di-GMP at either their
degenerate active site or their RXXD inhibition site.
These degenerate DGCs respond to c-di-GMP in several
ways. C-di-GMP may mediate participation of the DGC
in a regulatory cascade, as does PopA from C. crescentus,
PelD from Pseudomonas aeruginosa, and CdgA from
Bdellovibrio bacteriovorus which bind c-di-GMP to regu-
late cell cycle progression, biofilm formation, and preda-
tion, respectively [20-22]. Binding of c-di-GMP may be
required for proper localization of the protein akin to both
FimX from P. aeruginosa and SgmT from Myxococcus xan-
thus [23,24]. Additionally, degenerate DGCs may also re-
tain other roles independent of c-di-GMP binding. CdpA
in V. cholerae requires its degenerate GGDEF domain, but
not c-di-GMP, to retain its PDE activity, and the highly
degenerate GGDEF domain of YybT from Bacillus subtilis
exhibited ATPase activity [10,25]. In one case, a degenerate
DGC has been shown to be active as the Pectobacterium
atrosepticum DGC ECA3270 retains DGC activity despite
having a degenerate SGDEF active site motif [26]. Inter-
estingly, evidence is accumulating that DGCs and PDEs
themselves form protein complexes, and it is intriguing to
speculate degenerate DGCs impact these processes [27,28].
Here we investigate the degenerate V. cholerae DGC
VCA0965. We examined the ability of all 40 V. cholerae
DGCs to inhibit motility in semisolid agar, and weTable 1 Strain and plasmid list
Strain or plasmid Relevant features
Strain
Vibrio cholerae




pCMW75 pEVS143 backbone, overexpression of QrgB (Vi
pVCA0965 pEVS143 backbone, overexpression of VCA0965
pVCA0965-A Site pEVS143 backbone, overexpression of VCA0965
pVCA0965-I Site pEVS143 backbone, overexpression of VCA0965
pVCA0965-AI Site pEVS143 backbone, overexpression of VCA0965
pVCA0965(180–396) pET28b backbone, overexpression of VCA0965determined that VCA0965 was active in this assay. This
result was surprising as VCA0965 is a DGC that encodes
a degenerate AGDEF active site. Rather than functioning
as a receptor for c-di-GMP, our results suggest that
VCA0965, despite its degenerate active site motif, is
capable of c-di-GMP synthesis.
Methods
Bacterial strains and culture conditions
Strains used in this study are listed in Table 1. Site directed
mutants were generated using QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies) according
to the manufacturer’s protocols. E. coli and V. cholerae
strain C6706str2 were grown in LB at 35°C with shaking at
220 rpm unless otherwise indicated. LB was supplemented
with 100 μg mL-1 kanamycin as needed to maintain plas-
mids. Plasmids were induced with 0.1 mM isopropyl-β-D-
thiogalactoside (IPTG) unless otherwise specified.
Motility assay
Motility plates (60 mL) were prepared immediately be-
fore each assay from LB supplemented with 0.35% agar.
Plates, supplemented with 100 μg mL-1 kanamycin and
0.1 mM isopropyl-β-D-thiogalactoside (IPTG) as appro-
priate, were allowed to solidify for 1 to 4 hours prior to
use. Plates were inoculated from overnight cultures by
stabbing through the agar with a pipette tip, and left
undisturbed at room temperature for 1 hour before in-
version and incubation at 37°C for 20 hours. Motile
bacteria were digitally imaged using an Alpha Innotech
Red Gel Imager with white light and an 800 ms expo-
sure time. Images were processed to calculate colony
area by determining differential pixel density using
ImageJ software [31]. A sticker of known area was in-
cluded on each plate for normalization to obtain the co-
lony area in cm2. The initial motility screen (Figure 1)




brio harveyi DGC) under Ptac promoter [31]
under Ptac promoter [30]
E287A under Ptac promoter This study
R267A, D270A under Ptac promoter This study
R267A, D270A, E287A under Ptac promoter This study












































































































































































































Figure 1 Motility repression by Vibrio cholerae GGDEFs. The swimming motility of V. cholerae ectopically expressing each of its GGDEF
proteins was determined in 0.5% agar plates. Motility is normalized to the vector control, and the mean and standard deviation are shown.
23 GGDEF proteins significantly reduced motility (p < 0.05, black bars), while 7 others significantly increased motility (p < 0.05, white bars).
Gray bars are not significantly different from the vector control. VCA0965 is highlighted in the black box, and QrgB is a DGC from V. harveyi
known to be active in V. cholerae.
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flow cytometry biofilm assays
MBEC plates were prepared by inoculating 150 μL of
LB/well with a 1 to 1000 dilution from overnight V. cholerae
cultures. Wells were supplemented with 100 μg mL-1
kanamycin and 0.1 mM IPTG as needed. Plates were in-
cubated at 37°C with gentle aeration for 7 hours before
washing in PBS, fixing with 95% ethanol and staining
with 0.41% crystal violet in 10% ethanol. Crystal violet
was eluted in 160 μL of 95% ethanol. The optical density
at 600 nm (OD600) was determined using a Spectra Max
M5 spectrometer (Molecular Devices). To avoid satu-
ration, the elutions were also diluted 1 to 10 and the re-
sultant OD600 was measured. If the OD600 of the
undiluted elution exceeded 1, then the OD600 was calcu-
lated from the 1 to 10 dilution. Flow cytometry cultures
were prepared by diluting an overnight culture 1:100
in LB. Cultures were supplemented with kanamycin
and IPTG as needed and grown at 35°C and 220 rpm
for 4 hours. Flow cytometry analysis was performed
as described [32].
Determination of the intracellular concentration of c-di-GMP
Cultures were prepared by diluting an overnight culture
of V. cholerae 1:1000 into LB and grown to an OD600 be-
tween 0.6 and 1.0. Cultures were supplemented with
kanamycin and IPTG as needed. Samples were extracted
and analyzed by liquid chromatography coupled with
tandem mass spectromentry (LC-MS/MS) as previously
described [32] using an Acquity Ultra Performance li-
quid chromatography system (Waters) coupled with aQuattro Premier XE mass spectrometer (Waters). The
concentration of c-di-GMP was determined by quanti-
fying an 8-point standard curve of chemically synthesized
c-di-GMP (Biolog) ranging from 1.9 nM to 250 nM.
Protein purification
An overnight culture of E. coli JM109(DE3) (Promega)
containing the pVCA0965(180–396) vector was pre-
pared and used to inoculate LB broth supplemented
by 100 μg mL-1 kanamycin. The culture was grown at
37°C with shaking until an OD600 between 0.7-0.8 was
reached. The cells were then induced by addition of
IPTG to a concentration of 1 mM. The induced cells
were incubated between 16 and 18 hours at 16°C with
shaking. Following induction, cells were collected via cen-
trifugation in a Sorvall RC-5B Superspeed Centrifuge for
10 minutes at 2,678 g and 4°C. The pellet was then resus-
pended in lysis buffer (25 mM Tris-Cl (pH 8.0), 500 mM
NaCl, 5 mM 2-mercaptoethanol, 20 μg/mL DNase, one
tablet Roche protease inhibitor kit) and lysed using a
M-110P processor (Microfluidcs) 3 times at 20,000 psi.
Novagen Ni-NTA His-bind resin was equilibrated in bin-
ding buffer (25 mM Tris-Cl (pH 8.2), 500 mM NaCl,
20 mM imidazole, 5 mM 2-mercaptoethanol) and added
to the lysate. Resin and lysate were incubated for 60 mi-
nutes at 4°C with constant end over end rotation. After
incubation, lysate and resin were applied to a column
and allowed to flow to pack. The resin was washed three
times with small amounts of binding buffer. The protein
was then step eluted by the addition of imidazole elu-
tion buffer (25 mM Tris-Cl (pH 8.2), 500 mM NaCl,
DGC expressed
Figure 2 VCA0965 requires an intact active site to repress
motility. Quantification of motility as determined by quantifying
colony area (cm2) in V. cholerae strains expressing the indicated
proteins from a Ptac promoter on a plasmid. Proteins were induced
with 0.1 mM IPTG (gray bars). The mean and standard deviation
are indicated (* = p < 0.05, n = 3). In this and all subsequent figures
the strain designations are pCMW75 (QrgB) (an active DGC from
V. harveyi), pVCA0965 (WT VCA0965 expression plasmid), pVCA0965-I
(I-site mutant), pVCA0965-A (A-site mutant), and pVCA0965-AI (I-site/A-site
double mutant).
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100 mM, 200 mM, or 300 mM imidazole. VCA0965 was
determined to elute in the 200 mM and 300 mM imidazole
fractions. These fractions were concentrated on Amicon
Ultra Centrifugal Units by centrifugation at 16,000 g for 20
minutes at 4°C. Concentrated fractions were washed once
with dialysis buffer (30 mM Tris-Cl (pH 7.6), 100 mM
NaCl) and then stored at −80°C in 20% glycerol.
Determination of DGC activity
Purified proteins were diluted 1/25 and mixed with
0.015 mM GTP in reaction buffer (41 mM NaCl, 24 mM
Tris-Cl, 1.25 mM MgCl2) for 24 hours at room tem-
perature. Samples were then boiled for five minutes until
precipitate formed and centrifuged at 15,871 g for 10 min.
to remove precipitated proteins. The concentration of
c-di-GMP was determined using LC-MS/MS as described
above.
Results
Census of DGCs that regulate motility in Vibrio cholerae
Vibrio cholerae strain C6706str2 encodes 40 GGDEF
domain containing proteins which potentially function
as DGCs. As c-di-GMP represses motility in V. cholerae
[33], we determined which of the 40 GGDEFs repress
motility in laboratory conditions by individually over-
expressing each from a Ptac promoter on a plasmid and
measuring flagellar based swimming motility in 0.5%
agar plates. We chose to survey the activity of all DGCs
using a heterologous expression strategy, rather than
mutagenesis analysis, because this approach ensures that
each DGC is expressed in the conditions examined. Our
results indicated that 23 of the GGDEF encoding pro-
teins significantly repressed motility while 7 significantly
increased motility (Figure 1). All 7 of the proteins that
increase motility contain both a GGDEF domain and an
EAL domain. Therefore, we hypothesize that these pro-
teins likely possess net PDE activity resulting in de-
creased intracellular c-di-GMP. Interestingly, VCA0965
repressed motility 4.6-fold, yet it is predicted to be enzy-
matically inactive due to a non-canonical AGDEF active
site. For this reason, we sought to further understand
the role of VCA0965 in the regulation of c-di-GMP con-
trolled behaviors in V. cholerae.
The active site of VCA0965 is required for motility
inhibition
We hypothesized that VCA0965 was incapable of synthe-
sizing c-di-GMP and functioned as a c-di-GMP receptor
protein to repress motility. Consistent with previously stu-
died DGC effectors, c-di-GMP could bind VCA0965 at its
degenerate active site (referred to as the A-site) and/or its
RXXD allosteric inhibition site (referred to as the I-site)
[10,20,21]. To determine if the A-site and/or I-site werenecessary for motility repression, we mutated the VCA0965
I-site from RXXD to AXXA (VCA0965-I) and the
VCA0965 A-site from AGDEF to AGDAF (VCA0965-A).
We also constructed an allele of VCA0965 which
contained both the A-site and the I-site mutations
(VCA0965-AI). These mutant VCA0965 alleles were
ectopically expressed from a plasmid in V. cholerae and
then tested for the ability to repress swimming motility
(Figure 2). Confirming our previous findings, ectopic ex-
pression of WT VCA0965 repressed motility 3-fold in a
motility assay, as did the positive control QrgB, a DGC
from the related species Vibrio harveyi that has been shown
to be active in V. cholerae [34] (Figure 2). The I-site mutant
more robustly repressed motility than WT VCA0965. This
result demonstrated that the I-site is not required for moti-
lity repression. However, the A-site was necessary for this
regulation as expression of both the VCA0965-A and
VCA0965-AI proteins failed to inhibit motility (Figure 2).
VCA0965-I induces biofilm formation
Like many bacterial species, biofilm formation in V. cho-
lerae is induced by increased intracellular c-di-GMP [9].
As ectopic expression of VCA0965 was able to repress
motility, we determined whether ectopic expression of
VCA0965 would induce biofilm formation. Biofilm for-
mation was quantified using two approaches. First we
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concentration (MBEC) biofilm assay. Expression of the
positive control DGC, QrgB, induced biofilm formation
four fold above the vector control (Figure 3A). Although
overexpression of VCA0965 significantly inhibited mo-
tility, overexpression of VCA0965 did not affect biofilm
formation. This result could be due to high-specificity
signaling or differential activity of the DGC in these two
experiments (see Discussion). In contrast, overexpression
of VCA0965-I stimulated a 3-fold increase in biofilm for-
mation (Figure 3A). Analogous to our results measuring
motility, overexpression of VCA0965-A and VCA0965-AI
did not induce biofilms. This result indicated that the abil-
ity of the I-site mutant to induce biofilm formation was
dependent on the presence of an intact active site motif.
To confirm these results, we measured biofilm for-
mation using flow cytometry as previously described
[30]. This assay measures aggregate formation in liquid
cultures, which is driven by extracellular polysacchar-
ide production. Analysis of biofilms by flow cytometry
was indeed similar to the results of the MBEC assay in
that WT VCA0965 was unable to stimulate aggregate
formation, but the VCA0965-I mutant strongly stimu-
lated aggregate formation in an A-site dependent man-
ner (Figure 3B).
VCA0965 synthesizes c-di-GMP
The above findings that VCA0965 and/or its I-site mu-
tant were able to repress motility and induce biofilm
formation only with an intact AGDEF active site sug-
gested that VCA0965 was capable of influencing intra-
cellular c-di-GMP levels. To test this hypothesis, we
measured the impact of VCA0965, VCA0965-I, VCA
0965-A and VCA0965-AI overexpression on intracel-
lular c-di-GMP levels in V. cholerae using liquid chro-
matography coupled with tandem mass spectrometryFigure 3 Overexpression of the VCA0965-I mutant induces biofilm fo
formation of V. cholerae overexpressing wild type VCA0965 and its mutant
as measured by flow cytometry was determined by multiplying the mean
of aggregates relative to the total events measured. The mean and standar(LC-MS/MS). We observed that overexpression of
VCA0965 and VCA0965-I caused a 4- and 15-fold in-
crease, respectively, in the intracellular concentration of
c-di-GMP compared to a vector control (Figure 4). Neither
pVCA0965-A nor pVCA0965-AI caused a significant
change in c-di-GMP levels when overexpressed, as would
be expected if VCA0965 possessed DGC activity (Figure 4).
We obtained similar results if these variants of VCA0965
were expressed in E. coli (data not shown).
It remained possible that VCA0965 modulated c-di-
GMP levels by interacting with other components in the
cell, although these components would have to be con-
served between V. cholerae and E. coli. To further confirm
that VCA0965 is an active DGC, we purified VCA0965
and assessed its DGC activity in vitro. Due to the fact that
VCA0965 is predicted to contain five transmembrane
domains that span the inner membrane, it was neces-
sary for purification purposes to construct a truncated
version of VCA0965 composed exclusively of the cyto-
plasmic portion of the protein containing amino acids
180 to 396. VCA0965(180–396) was incubated with
12.5 µΜ GTP and synthesized c-di-GMP was quantified
using LC-MS/MS. Both VCA0965(180–396) and the posi-
tive control DGC, WspR(R242A) [35], produced c-di-
GMP with yields above 90% (Figure 5). LC-MS/MS ana-
lysis of VCA0965(180–396) revealed small amounts of
c-di-GMP even when GTP was not added. The presence
of this c-di-GMP is likely due to co-purification of c-di-
GMP bound to the I-site as has been previously observed
[36]. The WspR(R242A) positive control is an I-site mu-
tant and thus no co-purification of c-di-GMP was ob-
served. We attempted to define the kinetic parameters
of VCA0965 but the purified protein was unstable and
frequently precipitated from solution, leading to variable
results. This instability is likely because VCA0965 is an
inner membrane protein and we were only able to purifyrmation in an A-site dependent manner. (A) Mean biofilm
derivatives were measured using a MBEC assay. (B) Biofilm formation
forward scatter value of the aggregate population by the percentage

























Figure 4 VCA0965 increases the intracellular concentration of
c-di-GMP. Wild type VCA0965 and its mutant derivatives were
overexpressed in V. cholerae grown to an OD600 of 0.6-1.0, and the
resultant c-di-GMP levels were measured using LC-MS/MS. The
mean and standard deviation are indicated (*= p < 0.05, n = 3).
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that even though VCA0965 contains a degenerate active
site it is capable of c-di-GMP synthesis.Determining the plasticity of the first amino acid in the
active site of VCA0965
As a naturally occurring enzymatically active AGDEF
DGC has never been reported, we wondered what amino
acid substitutions in the first residue of this active site
would maintain DGC activity (amino acid residue 284
in VCA0965). To answer this question, we constructedFigure 5 VCA0965 (180–396) is an active DGC in vitro. The
cytoplasmic portion of VCA0965, VCA0965(180–396), was purified.
This protein and WspR(R242A) were incubated with and without
12.5 µM GTP overnight. The concentration of synthesized c-di-GMP
was determined by LC-MS/MS. The mean value and standard
deviation are shown (n = 3).mutants of VCA0965 containing all 19 amino acids in
the first position of the AGDEF active site and deter-
mined if expression of these proteins in V. cholerae re-
duced motility (Figure 6A). As expected, mutation of the
alanine to glycine generated an active DGC which inhib-
ited motility greater than the WT AGDEF enzyme, al-
though this difference was not statistically significant.
Although most VCA0965 mutants lost the ability to in-
hibit motility, mutation of the alanine to histidine and
methionine exhibited a significant inhibition of motility
greater than 2-fold.
The activity of the glycine, histidine, and methionine
substitutions was further examined by determining if in-
duction of these proteins significantly increased intracel-
lular c-di-GMP in V. cholerae. Indeed, all three of these
VCA0965 mutants significantly increased c-di-GMP
when induced compared to the uninduced controls; the
histidine and methionine mutations were statistically sig-
nificant (p < 0.05 using a one-tailed Student’s t-test)
while the glycine substitution bordered on statistical sig-
nificance with a p-value of 0.067 (Figure 6B). The Ptac
promoter used to induce these proteins is leaky account-
ing for the variation in c-di-GMP levels in the unin-
duced controls. All four active VCA0965 variants
increased c-di-GMP levels by 3-fold. These results indi-
cate that the first position of the VCA0965 active site is
somewhat flexible, maintaining activity with four differ-
ent amino acids.
Bioinformatic analysis of AGDEF active sites
Our results studying VCA0965 suggest that the AGDEF
active site is in fact capable of DGC activity. We deter-
mined the prevalence of this active site among GGDEF
proteins using the standalone version of NCBI’s PsiBlast
to scan the 28,254 sequences of GGDEFs in the Pfam
database [37]. We first determined the frequency of the
AGDEF active site motif among GGDEF domain con-
taining proteins, and found that approximately 1.6 per-
cent of GGDEFs have an AG(D/E)EF active site motif,
approximately half of which also encode a RXXD inhib-
ition site (Table 2). We further found that 23 percent of
AG(D/E)EF proteins originate from Vibrios. Only about
10 percent of the total GGDEFs derive from Vibrios
indicating the AG(D/E)EF active site is overrepresented
in this genus (Table 2). Finally, we found that the total
RXXD motif frequency in GGDEF proteins was 44 per-
cent, lower than the 57 percent frequency reported by
Christen et al. [19], but this could be due to the large dif-
ference in database size (>1000 sequences versus >20,000
sequences).
The N-terminal domains of GGDEF proteins typically
encode conserved domains that are thought to bind envir-
onmental signaling cues to control the associated enzyme

















































































































Figure 6 The active site of VCA0965 tolerates additional amino acid substitutions. (A) Substitution mutants of every amino acid in the first
position of the AGDEF active site of VCA0965 (residue 284) were constructed and examined for the ability to reduce motility of V. cholerae.
(B) The intracellular concentration of c-di-GMP from V. cholerae expressing WT VCA0965 or the GGDEF, HGDEF, and MGDEF mutants was determined
using LC-MS/MS. Open bars are the uninduced conditions while gray bars are induced with 0.1 mM IPTG. Error bars indicate the standard deviation
and statistical significance from the corresponding uninduced culture was determined using a one-tailed Student’s t-test (n = 3, *p < 0.05).
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with few amino acids present outside of the membrane.
To determine the conservation of this domain among
GGDEF proteins, we queried the GGDEFs in the Pfam
database with the N-terminal region of VCA0965(1–179).
Sixty-eight sequences were identified with homology to
VCA0965’s N-terminal region, with sixty-two of these pro-
teins containing an AG(D/E)EF active site motif and sixty-
three of these proteins originating from Vibrios (Table 3).
This suggests that this N-terminal domain is found pre-
dominantly in related Vibrios and is strongly associatedTable 2 Bioinformatic analysis of the frequency of the AG(D/E
Numb
prot
Total GGDEF domain containing proteins analyzed 28,2
Proteins containing an AG(D/E)EF motif 44
Proteins containing an AG(D/E)EF motif and an
RXXD motif
20
Proteins containing an AG(D/E)EF motif from Vibrio sp. 10
Known GGDEF domain containing proteins from
Vibrio sp.
294
Proteins containing an RXXD and an XG(D/E)EF motif 124with an AG(D/E)EF active site. Moreover, this analysis
shows that most of the GGDEFs encoding the AG(D/E)EF
active site we identified in Table 2 are not homologs of
VCA0965, suggesting other DGCs have evolved to use the
AGDEF active site to synthesize c-di-GMP.
Discussion
Here we show that VCA0965, which encodes a degener-
ate AGDEF active site, is an active DGC that synthesizes
c-di-GMP. Overexpression of VCA0965 represses motil-




















Proteins containing homology to VCA0965′s N terminus 68 0.24 100
Proteins containing an AG(D/E)EF motif and homology to
VCA0965′s N terminus
62 0.21 91.18
Proteins from Vibrio sp. containing homology to VCA0965′s
N terminus
63 0.22 92.65
Proteins from Vibrio sp. containing homology to VCA0965′s
N terminus and an AG(D/E)EF motif
61 0.21 89.71
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synthesis. To our knowledge, this is the first description of
an active DGC containing a naturally encoded AGDEF
active site motif and only the second description of an ac-
tive non-canonical DGC; the only other example being the
SGDEF containing ECA3270 from Pectobacterium atro-
septicum [26]. ECA3270 regulates Type 1 secretion and
was found to retain a reduced level of activity when the
active site was mutated to AGDEF. Interestingly, we ob-
served a loss of activity of VCA0965 when the first pos-
ition was mutation to serine. This suggests that other
amino acids in these DGCs have coevolved to tolerate
these non-degenerate substitutions in the first position of
their active site.
Retention of activity in ECA3270 and VCA0965 is sur-
prising when the steric constraints of the active site are
considered. Within the active site, the GGDEF motif is
located in a hairpin [39]. C-di-GMP bound at the active
site extends over this hairpin, specifically the first G in
the GGDEF motif. Although alanine is a conservative
change compared to glycine, we were surprised to find
that mutation of this alanine to the less conserved histi-
dine and methionine amino acids maintained an active
DGC. We would expect that larger amino acids at this
position should create steric interactions detrimental to
activity. It is not clear why these amino acids are toler-
ated over less drastic changes, such as valine, but we
predict these differences are driven by specific amino
acids flanking the active site in proximity to the hairpin.
As both ECA3270 and VCA0965 tolerate non-canonical
substitutions to the first position of their active sites, but
the amino acids that are tolerated appear to be different,
the flexibility of each DGC’s active site may follow its
own “rules” and caution must be used when determining
if noncanonical substitutions in the first residue of a
given GGDEF motif render a DGC inactive.
Contrary to what might be expected based on the
structure of the DGC domain, degeneracy at the first
amino acid is quite common among DGCs. 23.7% of all
DGCs are degenerate at one or more amino acids in the
GGDEF motif [1]. Of these, almost half vary at only one
amino acid and most of these variances occur at the first
amino acid [1]. The frequency of variance at the firstamino acid of the GGDEF motif despite the apparent
steric limitations of the DGC structure suggest that
there may be a high level of variance in DGC structure.
Our in silico bioinformatic analysis of the AGDEF motif
found that AG(D/E)EFs account for approximately 1.6
percent of DGCs, making this motif fairly common and
suggesting that AGDEFs may have a variant structure
that allows them to retain activity. How this variance im-
pacts function remains to be addressed.
Finally, we found that although VCA0965 is able to re-
press motility and increase intracellular c-di-GMP levels
when overexpressed, WT VCA0965 did not impact bio-
film formation. However, the lack of biofilm induction is
inconsistent as we have found that overexpression of
VCA0965 led to an approximately 6-fold increase in bio-
film formation in another study [32]. When biofilm for-
mation was measured using flow cytometry, no increase
in biofilm formation was observed—a result corrobo-
rated by Massie et. al. [32]. This inconsistency suggests
that at the levels we are inducing VCA0965 it is only
able to exert a slight effect on biofilm formation which
is highly dependent on experimental conditions. These
results are consistent with Massie et. al. who observed
that some DGCs were able to induce biofilm formation
at 12 µΜ c-di-GMP, the levels we determined are pro-
duced when VCA0965 is induced (Figure 4), while
others did not [32]. This differential induction of pheno-
types by distinct DGCs at analogous concentrations of
c-di-GMP is attributed to high-specificity signaling path-
ways. Therefore, it is not surprising for VCA0965 to
have an intermediate phenotype. However, removing
VCA0965 from feedback inhibition by mutation of the
RXXD site increases the activity of VCA0965 allowing it
to synthesize higher amounts of c-di-GMP and induce
robust biofilm formation when overexpressed.
Our results highlight that the first amino acid of the
GG(D/E)EF motif should be considered flexible in regards
to DGC activity. In combination with the finding for
ECA3270, a more accurate description of a functional
active site should be (G/S/A)G(D/E)EF. However, whether
enzymes which naturally encode a GG(D/E)EF will retain
DGC activity upon substitution of the first glycine to
serine or alanine remains to be determined. It is possible
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alterations of the first amino acid to remain functional.
Additional non-canonical active site motifs should be
assayed to determine if enzymatic activity of these
DGCs is widespread. Furthermore, structural analysis of
ECA3270 and VCA0965 can highlight how variance at
the first amino acid of the GGDEF motif can accommo-
date DGC activity.
Conclusions
The research presented here shows that the AGDEF
containing Vibrio cholerae DGC, VCA0965, is able to
synthesize c-di-GMP to control motility and biofilm
formation. Moreover, we found that addition of three
other amino acids, glycine, methionine, and histidine,
maintained DGC activity. Our results illustrate that the
first residue of the GG(D/E)EF active site in DGCs is
more flexible to substitutions than previously appreci-
ated. As many DGCs encode non-canonical amino acids
at this position, caution must be used when determining
the activity of these enzymes. Whether or not substitu-
tion of non-canonical amino acids at the first position
of the active site has important functional consequences
on DGC activity remains to be explored.
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